Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from NeuroPace ( (NPCE) ).
On January 28, 2025, NeuroPace announced its financial guidance for the year 2025, projecting revenue between $92 million and $96 million and a gross margin of 73% to 75%. The company also detailed its clinical and product development progress, including significant improvements in seizure reduction in its post-approval trial and the ongoing NAUTILUS pivotal trial aimed at expanding the RNS System’s use in drug-resistant idiopathic generalized epilepsy. NeuroPace plans to enhance its product offerings with an AI-powered seizure classifier tool and aims to achieve cash flow breakeven while expanding market reach through strategic objectives over the next three years.
More about NeuroPace
NeuroPace, Inc., based in Mountain View, California, is a medical device company specializing in epilepsy treatment. Its flagship product, the RNS System, is a brain-responsive platform designed to reduce or eliminate seizures, offering personalized, real-time treatment at the seizure source.
YTD Price Performance: 22.97%
Average Trading Volume: 96,654
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $438.3M
Learn more about NPCE stock on TipRanks’ Stock Analysis page.
